reports
EQS-News: Incannex Healthcare discusses A$13 million institutional pla...
EQS-News: Incannex Healthcare Ltd Incannex Healthcare discusses A$13 million institutional placement 06.12.2022 / 20:00 CET/CEST The issuer is solely responsible for the content of this announcement. Contact DetailsProactive InvestorsJonathan Jackson News Source: News Direct 06.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive...
EQS-News: Incannex kicks off manufacture of skin therapeutics
EQS-News: Incannex Healthcare Ltd Incannex kicks off manufacture of skin therapeutics 29.11.2022 / 21:20 CET/CEST The issuer is solely responsible for the content of this announcement. Contact DetailsProactive InvestorsJonathan Jackson News Source: News Direct 29.11.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.Archive at -news.com Languag...
Incannex Healthcare (IXHL): Initiation — Addressing unmet needs via un...
Edison Investment Research Limited Incannex Healthcare (IXHL): Initiation — Addressing unmet needs via unique approach 30-Aug-2022 / 12:38 GMT/BST London, UK, 30 August 2022 Incannex Healthcare (IXHL): Initiation — Addressing unmet needs via unique approach Incannex Healthcare is an Australian biotech specializing in the development of treatments for chronic conditions through a unique approach. Specifically, the company is investigating the use of cannabinoids and psychedelics, leveraging its synergistic combination intellectual property. Most recently, it has achieved proo...
- Sean Conroy
Incannex Healthcare - Addressing unmet needs via alternative approach
Incannex Healthcare is an Australian biotech specializing in the development of treatments for chronic conditions through a unique approach. Specifically, the company is investigating the use of cannabinoids and psychedelics, leveraging its synergistic combination intellectual property (IP). Most recently, it has achieved proof-of-concept in Australia for IHL-42X, its lead asset for the treatment of obstructive sleep apnea (OSA). The company intends to file an investigational new drug applicatio...
- Sean Conroy
Incannex Healthcare - APIRx acquisition to bolster portfolio
Incannex Healthcare, an Australian cannabinoid and psychedelic medicines biotech, has announced that it has completed the acquisition of APIRx Pharmaceuticals (APIRx), a US biotechnology company focused on the development and manufacture of cannabinoid formulations. In an all-share transaction, Incannex has acquired 100% of the issued share capital in APIRx. APIRx’s pipeline consists of 22 clinical and pre-clinical therapeutic cannabinoid development programmes and an extensive intellectual prop...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.